Work

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5576

Authors: Mark Christopher Markowski, Hao Wang, Michael Thomas Schweizer, Michael Anthony Carducci, Channing Judith Paller, Benjamin A. Teply, Mario A. Eisenberger, Jun Luo, Emmanuel S. Antonarakis, Samuel R. Denmeade

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Washington, Fred Hutch Cancer Center, Johns Hopkins Medicine, University of Nebraska Medical Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3029972244

Cites:

Cited by: 1

Related to: 10